Jul 22
|
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
|
Jul 21
|
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
|
Jul 18
|
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
|
Jul 17
|
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
Jul 16
|
3 Penny Stocks With Market Caps Over $30M To Consider
|
Jul 9
|
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
|
Jun 17
|
3 Promising Penny Stocks With Market Caps Over $10M
|
Jun 13
|
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
|
May 28
|
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
|
Apr 24
|
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
|
Apr 11
|
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
Apr 7
|
Talkspace And 2 Other Promising Penny Stocks
|
Mar 3
|
Connect Biopharma to Present at Two Upcoming Investor Conferences
|
Feb 28
|
Connect Biopharma Holdings And Two Other Promising Penny Stocks To Watch
|
Dec 31
|
3 US Penny Stocks With Market Caps Under $400M To Consider
|
Sep 10
|
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
|
Sep 5
|
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
|
May 7
|
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
|
May 2
|
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
|
Apr 16
|
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
|